B. Howng

Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

O. Vasiljeva, M. Belvin, I. Melero, 2021, Proceedings of the National Academy of Sciences.

The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice

O. Vasiljeva, G. V. van Dongen, D. Vugts, 2020, Theranostics.

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

O. Vasiljeva, M. Belvin, W. Kavanaugh, 2021, Cancer Immunology Research.

Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable Antibodies

O. Vasiljeva, Michael B Winter, B. Howng, 2021, Pharmaceutics.

Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue

O. Vasiljeva, E. D. de Vries, L. Broer, 2020, Clinical Cancer Research.